

CURRICULUM VITAE

Name: Fabrizio PIN, PhD

Work Address: 980 W. Walnut Street, R3 C521-C550,
Indianapolis, IN 46202

Mobile: + 1 317 998 0156

Email: fpin@iu.edu

EDUCATION

- 2011-2016, PhD in Experimental Medicine and Therapy, 01/2016.
School of Life and Health Sciences, University of Turin, Italy.
Dissertation: *Cancer cachexia: pathogenesis and potential therapeutic interventions*
- 2007-2010, Master in Sanitary Biology, 04/2011.
School of Science, Degree in Health Biology, University of Turin, Italy.
Dissertation: *Erythropoietin and exercise training: a combined approach to counteract cancer cachexia.*
- 2004-2007, Bachelor in Biological Sciences, 03/2008.
School of Science, Degree in Biological Sciences (Biomolecular), University of Turin, Italy.

RESEARCH EXPERIENCE

- 07/2022 – Present
Assistant Professor, Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
- 09/2021 – 7/2022
Assistant Scientist, Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
- 05/2017 – 08/2021
Post-Doctoral Fellowship, Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA (Supervisors: Prof. Lynda F. Bonewald and Prof. Andrea Bonetto).
- 05/2016 – 1/2017
Post-Doctoral Fellowship, Department of Clinical and Biological Sciences, University of Torino, Italy (Supervisor: Prof. Paola Costelli).
- 11/2014 – 03/2015
Visiting PhD student, Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA (Supervisor: Prof. Denis C. Guttridge).
- 01/2012 – 01/2016
PhD student, Graduate School in Life and Health Sciences, University of Torino, Italy (Supervisor: Prof. Paola Costelli).
- 01/2011 – 12/2011
Research Fellow, Department of Experimental Medicine and Oncology, University of Torino, Italy (Supervisor: Prof. Paola Costelli).
- 10/2009 – 05/2010
Visiting Student (Erasmus Program), Department of Biochemistry and Molecular Biology, Universitat de Barcelona, Spain (Supervisor: Prof. Josep M. Argilés).

TEACHING

- Participation in the project “La Scienza dal Vivo” (2012 and 2013), aimed to approach secondary school students to Biology.
- **Immunology Laboratory** (BS in Biological Sciences): isolation of peripheral blood cells, immunological detection of a protein (Western blotting).
- Training of undergraduate students during their laboratory experience for Bachelor and/or Master Theses preparation.
- **G801 Neuromusculoskeletal Cell Biology**. Indiana Center for Musculoskeletal health, Indiana University, Indianapolis, IN. Format: Lecture (2 hours). Enrollment: 10 graduate students were in attendance. Role: Lecturer. 7/2022

Role: Primary Mentor and Supervisor

- Marina Ricci, undergraduate students, laboratory experience for Master Theses preparation.
- Federica Conta, undergraduate students, laboratory experience for Master Theses preparation.
- Katherine E. Couch, Student enrolled in the Indiana CTSI Project STEM Internship Program, Indiana University.
- Kyra C. Colston, Student enrolled in the Indiana CTSI Project STEM Internship Program, Indiana University.
- Carlie E. Erne, Research Technician Trainee, Indiana University.
- Alyson L. Essex, Graduate student, Indiana University, laboratory experience for PhD Theses preparation.
- Maya Gutierrez, Student enrolled in the Indiana CTSI Project STEM Research Program, Indiana University.
- Austin Keith, Student enrolled in the Indiana CTSI Project STEM Research Program, Indiana University.
- Thang Cin Uap, Student enrolled in the Indiana CTSI Project STEM Research Program, Indiana University.
- Anika Shimonty, Graduate student, Indiana University, laboratory experience for PhD Theses preparation.

LANGUAGE SKILLS

- **Italian:** *Native speaker*
- **English:** *Reading skills: Good, Writing skills: Good, Verbal skills: Good*
- **Spanish:** *Reading skills: Good, Writing skills: Good, Verbal skills: Good*

PROFESSIONAL HONORS AND AWARDS:

Research

Best Poster presentation (1st place) 6/2022
15th International Conference on Cachexia Sarcopenia and muscle wasting – Lisbon, Portugal

Invited speaker 8/2021
Cancer cachexia Conference, Next generation Researcher in Cancer Cachexia. Presentation title: “*Mitochondrial-targetting MitoQ improves muscle atrophy, weakness and oxidative metabolism in C26 tumor-bearing mice*”.

Invited speaker 11/2020
ASBMR member Spotlight Series. Presentation title: “*RANKL blockade reduces cachexia and bone loss induced by non-metastatic cancer*”.

Best Oral Presentation (1st place) 10/2020
IUSM Postdoc Symposium Indianapolis, IN

Invited speaker 8/2019
Bone and Muscle: the Mechanical and Beyond Conference. Indianapolis, IN, USA. Presentation title: “*Preservation of bone mass by anti-resorptive treatments improves skeletal muscle mass and function in a non-metastatic model of cancer cachexia*”.

Best Oral presentation (1st place) 12/2019
12th International Conference on Cachexia Sarcopenia and muscle wasting – Berlin, Germany

Best Oral Presentation (1st place) 10/2018
IUSM Postdoc Symposium Indianapolis, IN

Best Poster Presentation (2nd place) 10/2017
IUSM Postdoc Symposium Indianapolis, IN

GRANTS AND SCHOLARSHIPS

- Young Investigator Travel Grant, American Society for Bone and Mineral Research (ASBMR), ASBMR 2019 Symposium – Orlando, FL (08/2019).
- Post-Doctoral Fellowship, Department of Clinical and Biological Sciences, University of Torino, Italy (05/2016 – present).
- Grant for training activities in Biotechnology, CIB - Consorzio Interuniversitario Biotecnologie, Italy (11/2014 – 03/2015).
- PhD Scholarship, PhD School in Life and Health Sciences, Medicine and Experimental Therapy Program, University of Torino, Italy (01/2012 – 01/2016).
- Scholarship, Department of Experimental Medicine and Oncology, University of Torino. Experimental investigation on cancer cachexia and muscle wasting (01/2011 – 12/2011).
- Fellowship, Erasmus Project. Department of Biochemistry and Molecular Biology, Universitat de Barcelona, Spain (2009/2010).

ACTIVE RESEARCH GRANT/SUPPORT

Deletion of FNDC5/Irisin protects against cancer-induced cachexia syndrome.
Biomedical Research Grant (BRG)
Principal Investigator
Direct: \$50,000 04/2022 – 03/2023

COMPLETED RESEARCH GRANT/SUPPORT

Detection of osteoclast-mediated bone resorption in non-metastatic tumor hosts by imaging of Cathepsin K activity.
Postdoc Challenge Award (Indiana CTSI-Clinical and Translational Sciences Institute).
Principal Investigator
Direct: \$5,000 04/2019-03/2020

PENDING RESEARCH GRANT/SUPPORT

Deletion of FNDC5/Irisin protects against cancer-induced cachexia syndrome.
R21 (NIH/NCI)
Principal Investigator
Direct: \$275,000 07/2023 – 03/2025

Bone-targeting strategies to improve musculoskeletal health in cancer survivors.
IUSCCC Junior Faculty Special Interest Group (SIG)
Principal Investigator
Direct: \$45,000 10/2022 – 10/2023

SUBMITTED BUT NOT FUNDED RESEARCH GRANT/SUPPORT

Deletion of FNDC5/Irisin protects against cancer-induced cachexia syndrome.
R21 (NIH/NCI)
Principal Investigator
Direct: \$275,000 07/2022 – 03/2024

Deletion of FNDC5/Irisin protects against cancer induce cachexia Syndrome

Pfizer Research GRANT 2021/2022 Global Cachexia ASPIRE

Principal Investigator

Direct: \$250,000

06/2022 – 05/2024

MEMBER

Indiana Center for Musculoskeletal Health. 2021-present

IU Melvin and Bren Simon Comprehensive Cancer Center. 2022

Cancer Cachexia Society. 2020-present

ASBMR (American Society for Bone and Mineral Research). 2018-present.

SCWD (Society on Sarcopenia, Cachexia and Wasting Disorders). 2018-present

IIM (Interuniversity Institute of Myology). 2012-2020

PROFESSIONAL SERVICE

Manuscript Peer-Review:

- Journal of Cancer 2018-present (2)
- Journal of Cellular and Molecular Medicine 2019-present (1)
- International Journal of Molecular Science 2020-present (3)
- Frontiers in Pharmacology 2020-present (1)
- Antioxidants 2021-present (2)
- JCSM 2021-present (6)

PUBLICATIONS

1. Huot JR, **Pin F**, Chatterjee R, Bonetto A. PGC1 α overexpression preserves muscle mass and function in cisplatin-induced cachexia. *J Cachexia Sarcopenia Muscle*. 2022 Jul 28. doi: 10.1002/jcsm.13035. Epub ahead of print. PMID: 35903870.
2. Essex AL, Huot JR, Deosthale P, Wagner A, Figueras J, Davis A, Damrath J, **Pin F**, Wallace J, Bonetto A, Plotkin LI. *TREM2 R47H variant causes distinct age- and sex-dependent musculoskeletal alterations in mice*. *J Bone Miner Res*. 2022 May 16. doi: 10.1002/jbmr.4572. Epub ahead of print. PMID: 35575023.
3. **Pin F**, Huot JR, Bonetto A. *The mitochondrial-targeting agent MitoQ improves muscle atrophy, weakness and oxidative metabolism in C26 tumor-bearing mice*. *Front Cell Dev Biol*. 2022 Mar 22;10:861622. doi: 10.3389/fcell.2022.861622. eCollection 2022.
4. **Pin F***, Beltrà M*, Castillo LG, Pardini B, Birolo G, Matullo G, Penna F, Guttridge D, Costelli P. *Extracellular vesicles derived from tumor cells as a trigger of energy default in the skeletal muscle*. *J Cachexia Sarcopenia Muscle*. 2022 Feb;13(1):481-494. doi: 10.1002/jcsm.12844. Epub 2021 Dec 20. * These authors contributed equally to this work.
5. **Pin F**, Jones AJ, Huot JR, Narasimhan A, Zimmers TA, Bonewald LF, Bonetto A. *RANKL Blockade reduces cachexia and bone loss induced by non-metastatic ovarian cancer*. *J Bone Miner Res*. 2022 Mar;37(3):381-396. doi: 10.1002/jbmr.4480. Epub 2021 Dec 13.

6. Beltrà M, **Pin F**, Ballaro R, Costelli P and Penna F. *Mitochondrial Dysfunction in Cancer Cachexia: Impact on Muscle Health and Regeneratio*. *Cells*. 2021 Nov 12;10(11):3150. Doi:10.3390/cells10113150.
7. **Pin F**, Prideaux M, Bonewald LF, Bonetto A. *Osteocytes and Cancer*. *Curr Osteoporos Rep*. 2021 Dec;19(6):616-625. doi: 10.1007/s11914-021-00712-9. Epub 2021 Nov 13.
8. O'Connell TM, Golzarri-Arroyo L, **Pin F**, Barreto R, Stephanie D, Couch M, Bonetto A. (2021). *Metabolic biomarkers for the early detection of cancer cachexia*. *Frontiers in Cell and Developmental Biology*. *Front Cell Dev Biol*. 2021 Sep 21;9:720096. doi: 10.3389/fcell.2021.720096. eCollection 2021.
9. Huot JR, **Pin F**, Bonetto A. *Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity*. *Am C Cancer Res*. 2021 Jun 15;11(6):2990-3001. eCollection 2021.
10. **Pin F**, Prideaux M, Huot JR, Essex AL, Plotkin LI, Bonewald LF, Bonetto A. *Non-bone metastatic cancers promote osteocyte-induced bone destruction*. *Cancer Lett*. 2021 Jul 4;S0304-3835(21)00324-4. doi: 10.1016/j.canlet.2021.06.030
11. **Pin F**, Bonewald LF, Bonetto A. *Role of myokines and osteokines in cancer cachexia*. *Exp Biol Med (Maywood)*. 2021 Apr 25: 15353702211009213. doi: 10.1177/15353702211009213.
12. Ballaro R, Lopalco P, Audrito V, Beltra' M, **Pin F**, Angelini R, Costelli P, Corcelli A, Bonetto A, Szeto HH, O'Connell TM, Penna F. *Targeting Mitochondria by SS-31 Ameliorates the Whole Body Energy Status in Cancer- and Chemotherapy-Induced Cachexia*. *Cancer (Basel)*. 2021 Feb 18;13(4):850.
13. Kim HG, Huot JR, **Pin F**, Bin Guo, Bonetto A and Nader GA. *Reduced rDNA transcription diminishes ribosomal capacity and protein synthesis in cancer cachexia*. *FABES J*. 2021 Feb;35(2):e21335.
14. Huot JR, **Pin F**, Essex AL, Bonetto A. *MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer*. *Int J Mol Sci* 2021 Feb 2;22(3):1486.
15. Huot JR, **Pin F**, Narasimhan A, Novinger LJ, Keith AS, Zimmers TA, Willis MS, Bonetto A. *ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia*. *J Cachexia Sarcopenia Muscle*. 2020 Nov 16. doi: 10.1002/jcsm.12642. Epub ahead of print. PMID: 33200567.
16. Huot JR, Novinger LJ, **Pin F**, Narasimhan A, Zimmers TA, O'Connell TM, Bonetto A. *Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia*. *JCI Insight*. 2020 May 7;5(9). pii: 136687. doi: 10.1172/jci.insight.136687. PubMed PMID: 32298240.
17. Huot JR, Novinger LJ, **Pin F**, Bonetto A. *HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia*. *Dis Model Mech*. 2020 Jan 24;13(1). pii: dmm043166. Doi: 10.1242/dmm.043166. PubMed PMID: 31915140; PubMed Central PMCID: PMC6994937.
18. Cannito S, Foglia B, Villano G, Turato C, Delgado TC, Morello E, **Pin F**, Novo E, Napione L, Quarta S, Ruvoletto M, Fasolato S, Zanusi G, Colombatto S, Lopitz-Otsoa F, Fernández-Ramos D, Bussolino F, Sutti S, Albano E, Martínez-Chantar ML, Pontisso P, Parola M. *SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1 α and -2 α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets*. *Cancers (Basel)*. 2019 Dec 4;11(12). pii: E1933. doi: 10.3390/cancers11121933. PubMed PMID: 31817100.
19. Essex AL*, **Pin F***, Huot JR, Bonewald LF, Plotkin LI, Bonetto A. *Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice*. *Front Endocrinol (Lausanne)*. 2019 Nov 19;10:809. doi: 10.3389/fendo.2019.00809. eCollection 2019. PubMed PMID: 31803146; PubMed Central PMCID: PMC6877551. * These authors contributed equally to this work.

20. **Pin F**, Bonetto A, Bonewald LF, Klein GL. *Molecular Mechanisms Responsible for the Rescue Effects of Pamidronate on Muscle Atrophy in Pediatric Burn Patients*. *Front Endocrinol (Lausanne)*. 2019 Aug 7;10:543.
21. O'Connell TM, **Pin F**, Couch ME, Bonetto A. *Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia*. *Cancers (Basel)*. 2019 Aug 21;11(9).
22. **Pin F**, Novinger LJ, Huot JR, Harris RA, Couch ME, O'Connell TM, Bonetto A. *PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia*. *FASEB J*. 2019 Mar 20:fj201802799R. doi: 10.1096/fj.201802799R.
23. Ballarò R, Penna F, **Pin F**, Gómez-Cabrera MC, Viña J, Costelli P. *Moderate Exercise Improves Experimental Cancer Cachexia by Modulating the Redox Homeostasis*. *Cancers (Basel)*. 2019 Feb 28;11(3). pii: E285. doi: 10.3390/cancers11030285. PubMed PMID: 30823492.
24. Ranjbar K, Ballarò R, Bover Q, **Pin F**, Beltrà M, Penna F, Costelli P. *Combined Exercise Training Positively Affects Muscle Wasting in Tumor-bearing Mice*. *Med Sci Sports Exerc*. 2019 Feb 4. doi: 10.1249/MSS.0000000000001916.
25. **Pin F**, Barreto R, Couch ME, Bonetto A, O'Connell TM. *Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism*. *J Cachexia Sarcopenia Muscle*. 2019 Jan 24. doi: 10.1002/jcsm.12360.
26. Ballarò R, Beltrà M, De Lucia S, **Pin F**, Ranjbar K, Hulmi JJ, Costelli P, Penna F. *Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations*. *FASEB J*. 2019 Jan 17:fj201801862R.
27. **Pin F**, Couch ME, Bonetto A. *Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition*. *Curr Opin Support Palliat Care*. 2018 Dec;12(4):420-426.
28. **Pin F**, Barreto R, Kitase Y, Mitra S, Erne CE, Novinger LJ, Zimmers TA, Couch ME, Bonewald LF, Bonetto A. *Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia*. *J Cachexia Sarcopenia Muscle*. 2018 Jul 15. doi: 10.1002/jcsm.12311. [Epub ahead of print] PubMed PMID: 30009406.
29. Segatto M , Fittipaldi R , **Pin F**, Sartori R, Ko KD, Zare H, Fenizia C , Zanchettin G, Pierobon ES, Hatakeyama S, Sperti C, Merigliano S, Sandri M, Filippakopoulos P, Costelli P, Sartorelli V & Caretti G. *Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival*. *Nat. Commun*. DOI: 10.1038/s41467-017-01645-7.
30. Molinari F*, **Pin F***, Gorini S, Chiandotto S, Pontecorvo L, Penna F, Rizzuto E, Pisu S, Musarò A, Costelli P, Rosano G, Ferraro E. *The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice*. *J Cachexia Sarcopenia Muscle*. 2017 Nov 11. doi:10.1002/jcsm.12226. [Epub ahead of print] PubMed PMID: 29130633. * These authors contributed equally to this work.
31. Barreto R, Kitase Y, Matsumoto T, **Pin F**, Colston KC, Couch KE, O'Connell TM, Couch ME, Bonewald LF, Bonetto A. *ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass*. *Sci Rep*. 2017 Oct 31;7(1):14470.
32. **Pin F**, Minero VG, Penna F, Muscaritoli M, De Tullio R, Baccino FM, Costelli P. *Interference with Ca(2+)-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia*. *Front Physiol*. 2017 Apr 19;8:213.
33. Camperi A, **Pin F**, Costamagna D, Penna F, Menduina ML, Aversa Z, Zimmers T, Verzaro R, Fittipaldi R, Caretti G, Baccino FM, Muscaritoli M, Costelli P. *Vitamin D and VDR in cancer cachexia and muscle regeneration*. *Oncotarget*. 2017 Mar 28;8(13):21778-21793.

34. Aversa Z*, **Pin F***, Lucia S, Penna F, Verzaro R, Fazi M, Colasante G, Tirone A, Rossi Fanelli F, Ramaccini C, Costelli P, Muscaritoli M. *Autophagy is induced in the skeletal muscle of cachectic cancer patients*. Sci Rep. 2016 Jul 27;6:30340. * These authors contributed equally to this work.
35. Ferraro E, **Pin F**, Gorini S, Pontecorvo L, Ferri A, Mollace V, Costelli P, Rosano G. *Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine*. J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):449-57.
36. **Pin F**, Busquets S, Toledo M, Camperi A, Lopez-Soriano FJ, Costelli P, Argilés JM, Penna F. *Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations*. Oncotarget. 2015 Dec 22;6(41):43202-15.
37. Penna F, **Pin F**, Ballarò R, Baccino FM, Costelli P. *Novel investigational drugs mimicking exercise for the treatment of cachexia*. Expert Opin Investig Drugs. 2016;25(1):63-72.
38. Penna F, Busquets S, Toledo M, **Pin F**, Massa D, López-Soriano FJ, Costelli P, Argilés JM. *Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models*. J Lipid Res. 2013 Nov;54(11):3045-51.
39. Penna F, Costamagna D, **Pin F**, Camperi A, Fanzani A, Chiarpotto EM, Cavallini G, Bonelli G, Baccino FM, Costelli P. *Autophagic degradation contributes to muscle wasting in cancer cachexia*. Am J Pathol. 2013 Apr;182(4):1367-78.
40. Penna F, **Pin F**, Costamagna D, Reffo P, Baccino FM, Bonelli G, Costelli P. *Caspase 2 activation and ER stress drive rapid Jurkat cell apoptosis by clofibrate*. PLoS One. 2012;7(9):e45327.
41. Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, **Pin F**, Capdevila E, Madeddu C, López-Soriano FJ, Mantovani G, Macciò A, Argilés JM. *L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer*. Clin Nutr. 2012 Dec;31(6):889-95.
42. Penna F, Busquets S, **Pin F**, Toledo M, Baccino FM, López-Soriano FJ, Costelli P, Argilés JM. *Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise*. J Cachexia Sarcopenia Muscle. 2011 Jun;2(2):95-104.

MANUSCRIPT SUBMITTED/IN PREPARATION

- Kim HG, Huot J, **Pin F**, Belcher D, Bonetto A, Nader GA. *Divergent anabolic deficit and pro-inflammatory effectors of muscle wasting in xenograft and metastatic tumor models of colorectal cancer*. Under revision.
- Beltra M, **Pin F**, Costamagna D, Duellen R, Ballaro R, Garcia-Castillo L, Iannuzzi, A Sampaolesi M, Penna F, Costelli P. *PGC-1 α drives myogenesis against adipogenesis in regenerating skeletal muscle*. Under revision.
- Shimonti A, Bonewald L, **Pin F**. *Role of the osteocytes in musculoskeletal disease*. In preparation.
- Huot JR, **Pin F**, Bonetto A. *Therapy-induced toxicities associated with the onset of cachexia*. Submitted as invited chapter in 'Textbook of Systemic Effects of Advanced Cancer' (Springer Nature Switzerland AG, 2020).

CONFERENCES PROCEEDINGS

1. Oral and poster presentation, *Deletion of FNDC5/irisin protects against cancer induce cachexia syndrome*. 15th Cachexia Conference, Lisbon, Portugal, June 24-26, 2022.
2. Oral and poster presentation, *Deletion of FNDC5/irisin protects against cancer induce cachexia syndrome*. Indiana Center for Musculoskeletal Health (ICMH) retreat, Indianapolis, April 29, 2022.

3. Poster presentation, *RANKL blockade reduces cachexia and bone loss induced by non-metastatic cancer*. ASBMR, San Diego, CA October 1-4, 2021
4. Oral presentation, *Mitocondrial-targeting MitoQ improves muscle atrophy, weakness and oxidative metabolism in C26 tumor-bearing mice*. Virtual Cancer cachexia conference, September 27-29, 2021
5. Poster presentation, *The L enantiomer of β -aminoisobutyric acid (BAIBA), a contracting muscle metabolite, has positive effects on muscle *in vitro* and *in vivo**. Virtual ASBMR, September 11-15, 2020
6. Poster presentation, *Non-bone metastatic cancers promote osteocytic bone destruction*. Virtual ASBMR, September 11-15, 2020
7. Poster presentation, *RANKL blockade reduces cachexia and bone loss induced by non-metastatic cancer*. Virtual Cancer cachexia conference, September 10-11, 2020
8. Poster presentation, *Cachexia induced by non-bone metastatic cancers is accompanied by bone, cartilage and bone marrow destruction*. 12th Cachexia Conference, Berlin, Germany, December 6-8, 2019
9. Poster presentation, *Effect of RANKL-producing compared to non-RANKL producing tumors on muscle and bone*. ASBM, Orlando, FL September 2019
10. Poster presentation, *Mechanism responsible for pamidronate rescue of post-burn muscle loss in children: an ex vivo study in C2C12 myotubes*. ASBM, Montreal, CA September 2018
11. Poster presentation, *Modulation of PDK4 drives metabolic alterations and skeletal muscle atrophy in cancer cachexia*, Cancer cachexia conference, Philadelphia, US, September 2018
12. Poster presentation *Cancer- and chemotherapy-induced cachexia yield distinct metabolic perturbations*. 10th Metabolomics Meeting, Seattle, WUS, June 2018
13. Poster presentation *Cancer- and chemotherapy-induced cachexia yield distinct metabolic perturbations*. 10th Cachexia Conference, Rome, Italy, December 2017.
14. Oral presentation *Tumor-derived microvesicles: new players in cancer-induced muscle wasting*. Abstract 2-21, 8th Cancer Cachexia Conference, Paris, France, December 4-6th, 2015.
15. Poster presentation *Tumor-derived microvesicles: new players in cancer-induced muscle wasting*. X Meeting of the Interuniversity Institute of Myology, San Bartolomeo, Italy, October 1-4th, 2015.
16. Poster presentation *PGC-1 α overexpression promotes myogenesis: relevance to cancer-induced muscle wasting*. EMBO Workshop, Ascona, Switzerland, September 20-25th, 2015.
17. Oral presentation *PGC-1 α counteracts cancer-induced muscle wasting in female mice*. abstract 40, X Meeting of the Interuniversity Institute of Myology, Monteriggioni, Italy, October 10-13th, 2013.
18. Oral presentation *Impairment of myogenic markers in human muscle wasting*. Abstract 41, page 7, IX Meeting of the Interuniversity Institute of Myology, Acaya, Italy, October 12-14th, 2012.
19. Poster presentation *Bed rest-induced muscle wasting is associated with modulation of myogenic markers*. Abstract 1-13, page 212. 6th Cancer Cachexia Conference, Milan, Italy, December 8-10th, 2011.

QUICK ONLINE LINKS

Scopus [Pin, Fabrizio - Author details - Scopus](#)

Researchgate [Fabrizio Pin \(researchgate.net\)](#)